• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

By: Acadia Pharmaceuticals Inc. via Business Wire
April 23, 2025 at 16:05 PM EDT

Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time.

The webcast will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuro-psychiatric and neuro-rare diseases. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250423396415/en/

Contacts

Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

ir@acadia-pharm.com

More News

View More
3 Defensive Stocks to Buy as Economic Uncertainty Lingers
Today 12:04 EDT
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CLX COST CVX
3 Dividend Hikes That Signal Renewed Strength in 2025
Today 11:34 EDT
Via MarketBeat
Topics Economy
Tickers ACN F GE GM HON THO
3 Sustainable Stocks Benefiting From the AI Energy Surge
Today 10:33 EDT
Via MarketBeat
Topics Artificial Intelligence Economy Government
Tickers HUBB NEE XYL
NVIDIA Analysts Lift Targets: What It Means for the Stock Price
Today 9:22 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers NVDA
Fastenal Stock Pulls Back in October—Is It Time to Buy FAST?
Today 8:21 EDT
Via MarketBeat
Tickers FAST
Recent Quotes
View More
Symbol Price Change (%)
GOOG  247.38
+2.75 (1.12%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap